Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | SDHA | P31040 | 2/20 | 0.42 |
| ▸ | CALML3 | P27482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890813 | 0.98 | DPP4 (0.45) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL2109029 | 0.98 | DPP4 (0.45) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL2108789 | 0.94 | DPP4 (0.44) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL541170 | 0.89 | DPP4 (0.47) | DPP4CHRM2DRD1LMNACALML3 | |
| SCHEMBL541976 | 0.89 | DPP4 (0.47) | DPP4CHRM2DRD1LMNACALML3 | |
| SCHEMBL6810285 | 0.89 | DPP4 (0.44) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL6809814 | 0.89 | DPP4 (0.46) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL4635165 | 0.89 | DPP4 (0.46) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL10063624 | 0.89 | DPP4 (0.42) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL2109049 | 0.89 | DPP4 (0.42) | DPP4CHRM2DRD1MAOALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993469-B2 | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections | Morphochem Aktiengesellschaft Für Kombinatorishe Chemie (DE) | 2018-06-12 | — | — | US | claimed |
| US-11261205-B2 | Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases | MORPHOCHEM GMBH (DE) | 2022-03-01 | — | — | US | disclosed |
| CN-112089714-A | Oxazolidinone-quinolone hybrid antibacterial agents for the parenteral treatment or prophylaxis of bacterial diseases | 莫弗凯姆有限公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20200392168-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2020-12-17 | — | — | US | disclosed |
| US-10723746-B2 | Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2020-07-28 | — | — | US | disclosed |
| EP-3517106-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20190111046-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMB CHEMIE (DE) | 2019-04-18 | — | — | US | disclosed |
| EP-3003289-B1 | ADMINISTRATION OF OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMB CHEMIE (DE) | 2019-02-20 | — | — | EP | disclosed |
| US-9993469-B2 | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections | Morphochem Aktiengesellschaft Für Kombinatorishe Chemie (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9993469-B2 | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections | Morphochem Aktiengesellschaft Für Kombinatorishe Chemie (DE) | 2018-06-12 | — | — | US | disclosed |
| US-8158797-B2 | Oxazolidinone-quinolone hybrid antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-04-17 | — | — | US | disclosed |
| EP-1709044-B1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1709044-B1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1620098-B1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392168-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES | NQO2, QARS1, RECQL | DPP4 408/4885CHRM2 4779/4885DRD1 1952/4885 |
| US-20190111046-A1 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS | OXA1L, NQO2, NQO1 | DPP4 137/4885CHRM2 4850/4885DRD1 3464/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | DPP4 1601/4885CHRM2 4628/4885DRD1 1207/4885 |
| US-10723746-B2 | Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases | NQO2, OXA1L, QARS1 | DPP4 383/4885CHRM2 4776/4885DRD1 1963/4885 |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | OXA1L, TOP1, TOP2A | DPP4 1036/4885CHRM2 4878/4885DRD1 1894/4885 |
| US-11261205-B2 | Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases | NQO2, QARS1, RECQL | DPP4 408/4885CHRM2 4779/4885DRD1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.